** Shares of Ascentage Pharma Group International 6855.HK jump 12.3% to HK$43.45, a peak since Jan. 6
** Stock on track for biggest one-day pct rise since Aug. 26, 2024
** Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical 4502.T, said on Tuesday it was targeting a valuation of $1.75 bln in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year
** Ascentage, which is focused on developing and commercializing therapies that target malignancies, is looking to raise $149 mln by offering about 7.3 mln American depositary shares at $20.34 each
** Shares of Takeda Pharmaceutical 4502.T up 0.2%
** Hong Kong's healthcare index .HSCIH slips 0.5% and Hang Seng Index .HSI falls 1.4%
** Ascentage stock soared 66.5% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。